Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antimalarials. A risk-benefit analysis

F Nosten1, R N Price

  • 1Shoklo Malaria Research Unit, Mae Sot, Tak Province, Thailand.

Drug Safety
|April 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A model for malaria treatment evaluation in the presence of multiple species.

Epidemics·2023
Same author

A Drug Repurposing Approach Reveals Targetable Epigenetic Pathways in <i>Plasmodium vivax</i> Hypnozoites.

bioRxiv : the preprint server for biology·2023
Same author

TB outcomes and mortality risk factors in adult migrants at the Thailand-Myanmar border.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

Tenofovir for prevention of mother to child transmission of hepatitis B in migrant women in a resource-limited setting on the Thailand-Myanmar border: a commentary on challenges of implementation.

International journal for equity in health·2020
Same author

Retrospective Review of Documentation Practices of Hepatitis B Immunoglobulin, Birth Dose, and Vaccination at the Hospital of Birth, in Thai Nationals and Migrants in Northern Thailand.

Open forum infectious diseases·2020
Same author

Feeding practices and risk factors for chronic infant undernutrition among refugees and migrants along the Thailand-Myanmar border: a mixed-methods study.

BMC public health·2019
Same journal

Implementation Aspects of a Medicines Shortage Policy Tool: Evidence from Australia's Serious Scarcity Substitution Instruments.

Drug safety·2026
Same journal

Availability and Communication of Risk Management Strategies for Pregnancy Category X Medicines across Australian Medicine Information Sources.

Drug safety·2026
Same journal

The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis.

Drug safety·2026
Same journal

Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis.

Drug safety·2026
Same journal

Developing a Hierarchical Algorithm to Identify Pregnancies and Determine Gestational Age from Nationwide Linked Health Data in Taiwan.

Drug safety·2026
Same journal

Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis.

Drug safety·2026
See all related articles

New antimalarial drugs offer hope but face challenges. Artemisinin derivatives are promising but need more data, while mefloquine and halofantrine have limitations and emerging resistance concerns.

Area of Science:

  • Tropical medicine
  • Pharmacology

Background:

  • Over 40% of the global population resides in malaria-endemic regions.
  • Limited antimalarial drug options exist for Plasmodium falciparum.
  • Recent advancements have introduced new treatment possibilities.

Purpose of the Study:

  • To review recently developed antimalarial drugs.
  • To discuss their efficacy, tolerability, and limitations.
  • To address the growing threat of drug resistance.

Main Methods:

  • Review of current literature on antimalarial drug development.
  • Analysis of clinical data for mefloquine, halofantrine, and artemisinin derivatives.
  • Assessment of drug resistance patterns and potential therapeutic strategies.

Related Experiment Videos

Main Results:

  • Mefloquine: effective for prophylaxis, single-day regimen, but rare severe adverse effects and emerging resistance.
  • Halofantrine: rapid action, well-tolerated, but expensive, cross-resistance, and cardiotoxicity concerns.
  • Artemisinin derivatives: rapid, well-tolerated, cost-effective, but require further pharmacokinetic and toxicity data for regulatory approval.

Conclusions:

  • New antimalarials like artemisinin derivatives represent significant progress.
  • Drug resistance remains a critical challenge for all antimalarials.
  • Combination therapy, such as mefloquine with artemisinin derivatives, may be a strategy to combat resistance.